Nanopath has raised $25.0M in Series B funding. The molecular diagnostics company is backed in the round by Norwest Ventures, SV Health Investors' MedTech Convergence Fund, Labcorp Venture Fund, Elderberry Ventures, GingerBread Capital, and Alumni Ventures.
Nanopath is working to upend traditional testing methodologies, aiming to deliver laboratory-quality information within a single office visit.












